{"id":562270,"date":"2021-09-09T12:18:01","date_gmt":"2021-09-09T12:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=562270"},"modified":"2021-09-09T12:18:01","modified_gmt":"2021-09-09T12:18:01","slug":"vasoocclusive-crisis-epidemiology-forecast-report-2030-vasoocclusive-crisis-epidemiology-analysis-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vasoocclusive-crisis-epidemiology-forecast-report-2030-vasoocclusive-crisis-epidemiology-analysis-2030-delveinsight_562270.html","title":{"rendered":"Vaso-Occlusive Crisis Epidemiology Forecast Report 2030 | Vaso-Occlusive Crisis Epidemiology Analysis 2030 | DelveInsight"},"content":{"rendered":"
\n
\"Vaso-Occlusive<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Vaso-Occlusive Crisis – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Vaso-Occlusive Crisis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n

DelveInsight launched a new report on Vaso-Occlusive Crisis Epidemiology Forecast, 2030.<\/a><\/strong><\/p>\n

The Vaso-Occlusive Crisis, or sickle cell crisis, is defined as pain resulting from tissue ischemia caused by vaso-occlusion, most commonly in the bone(s) and bone marrow. It is the most frequent, painful, and debilitating symptom of Sickle-cell disease (SCD) which typically occurs in the extremities, back, joints, abdomen, or chest. It is initiated and sustained by interactions among sickle cells, endothelial cells, and plasma constituents. <\/p>\n

DelveInsight’s ‘Vaso-Occlusive Crisis Epidemiology Forecast to 2030<\/strong>‘<\/a> report delivers an in-depth understanding of the disease, historical and forecasted Vaso-Occlusive Crisis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key highlights from the Vaso-Occlusive Crisis Epidemiology Report:<\/strong><\/p>\n

    \n
  1. \n

    Epidemiologic data indicate that 5.2% of patients with SCD have 3–10 episodes of severe pain every year. These severe and unpredictable painful attacks were responsible for >90% of acute hospital admissions and Vaso-occlusive crisis, which constitutes the major morbidity in SCD.<\/p>\n<\/li>\n

  2. \n

    Patients with homozygous sickle cell and sickle cell–β°-thalassemia have a higher frequency of Vaso-Occlusive Crisis than patients with hemoglobin SC and sickle cell–β+-thalassemia genotypes.<\/p>\n<\/li>\n<\/ol>\n

    Visit for more @ Vaso-Occlusive Crisis Epidemiology Insights<\/a><\/strong><\/p>\n

    Scope of the Vaso-Occlusive Crisis Epidemiology report:<\/strong><\/p>\n

      \n
    1. \n

      The Vaso-Occlusive Crisis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns<\/p>\n<\/li>\n

    2. \n

      The Vaso-Occlusive Crisis Epidemiology Report and Model provide an overview of the risk factors and global trends of the Vaso-Occlusive Crisis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)<\/p>\n<\/li>\n

    3. \n

      The report provides insight into the historical and forecasted patient pool of the Vaso-Occlusive Crisis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/p>\n<\/li>\n

    4. \n

      The report helps to recognize the growth opportunities in the 7MM concerning the patient population<\/p>\n<\/li>\n

    5. \n

      The report assesses the disease risk and burden and highlights the unmet needs of the Vaso-Occlusive Crisis<\/p>\n<\/li>\n

    6. \n

      The report provides the segmentation of the Vaso-Occlusive Crisis epidemiology<\/p>\n<\/li>\n<\/ol>\n

      Table of Contents:<\/strong><\/p>\n

      1. Key Insights<\/p>\n

      2. Executive Summary of Vaso-Occlusive Crisis<\/p>\n

      3. Vaso-Occlusive Crisis Epidemiology Overview at a Glance<\/p>\n

      4. Vaso-Occlusive Crisis: Disease Background and Overview<\/p>\n

      5. Epidemiology and Patient Population<\/p>\n

      6. Case Reports<\/p>\n

      7. Country Wise-Epidemiology of Vaso-Occlusive Crisis <\/p>\n

      8. Appendix<\/p>\n

      9. DelveInsight Capabilities<\/p>\n

      10. Disclaimer<\/p>\n

      11. About DelveInsight<\/p>\n

      Related Reports:<\/strong><\/p>\n

      Vaso-Occlusive Crisis Market<\/a><\/strong><\/p>\n

      DelveInsight’s ‘Vaso-Occlusive Crisis-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), <\/p>\n

      Vaso-Occlusive Crisis Pipeline<\/a><\/strong><\/p>\n

      “Vaso-Occlusive Crisis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Vaso-Occlusive Crisis market. A detailed picture of the Vaso-Occlusive Crisis pipeline landscape is provided, which includes the disease overview and Vaso-Occlusive Crisis treatment guidelines. <\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight’s ‘Vaso-Occlusive Crisis – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Vaso-Occlusive Crisis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-562270","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=562270"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=562270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=562270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=562270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}